BackgroundOcular metastases of cutaneous melanoma exclusive to the vitreous are a rare presentation and usually represent disseminated disease. Although traditionally associated with poor outcomes, recent developments in melanoma treatment have vastly improved prognosis.AimsTo review new targeted therapies for metastatic-melanoma.MethodsLiterature review of current clinical guidelines, systematic reviews and case series surrounding current recommended targeted therapies for metastatic-melanoma.ResultsNew targeted therapeutic agents offer improved treatment response, progression free survival, overall survival and have a better side-effect profile than traditional chemotherapy agents for metastatic melanoma.ConclusionTargeted agents for melanoma have improved patient prognosis and life expectancy, likely leading to reduced need for surgical intervention
